The Health Technologies Access Program (HTAP) is an WHO initiative that advances global equitable access to health and health safety products by widening regional innovation and manufacturing capacity. HTAP selects priority technologies and mobilizes partners to support their development, transfer and sustainable production to make them available for communities that need them.
Collaborative and demand on demand, HTAP aims to improve health security, meet unmet health needs and meet the access deficit to global health technologies. It covers both pandemic preparation and public health priorities outside the emergency room. HTAP initially focused on mRNA vaccines and diagnostics and will take into account other innovative technologies based on public health needs and their profitability analysis.
Htap succeeds COVVI-19 technology access pool (C-TAP) and fully integrates the Arnm technology transfer programwhich were originally established to cope with inequitable access to vaccines, drugs and other COVVI-19 health products.
Exploitation of WHO expertise, power and concession mandate, HTAP coordinates WHO and partners to support the manufacture of end -to -end health products. Thanks to two operating models, HTAP works to promote research and development (R&D) and secure technology and know-how transfer for health products.
The flagship activities include:
- Facilitation of technology transfer agreements Make quick diagnostic test technology (RDT) Biocapteur SD, a company whose headquarters are in the Republic of Korea.
- THE Arnm technology transfer programwhich works with 15 PRFR manufacturers to improve health safety by establishing sustainable and local mRNA manufacturing capacities. The program aims to establish R&D consortiums focused on 8 targets (including diseases as well as on components to manufacture products based on mRNA) to develop commercially viable mRNA products that can be manufactured by participating partners. These targets approach local and regional priority diseases, such as dengue and diseases of the foot in hand in Southeast Asia and influenza and leishmaniasis in Latin America. The objective is to establish a sustainable mRNA production, therefore in the event of an emergency in terms of health, such as a pandemic, it can be quickly reused to deal with the new threat.
- Partnerships with Public R&D institutesThe SREE Chitra Trunal Institute for Medical Sciences and Technology (SCTIMT) in India and the University of CAP (UCT) in South Africa. While evolving, these collaborations should extend fair access to innovative technologies, in particular by linking technology developers with manufacturing partners and facilitating technology transfer.